

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Bosentan

INITIATION – Pulmonary arterial hypertension

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Patient has pulmonary arterial hypertension (PAH)
- and PAH is in Group 1, 4 or 5 of the WHO (Venice) clinical classifications
- and PAH is at NYHA/WHO functional class II, III, or IV

- Bosentan is to be used as PAH monotherapy

and

- Patient is intolerant or contraindicated to sildenafil
- or Patient is a child with idiopathic PAH or PAH secondary to congenital heart disease

or

- Bosentan is to be used as PAH dual therapy

and

- Patient has tried a PAH monotherapy for at least three months and failed to respond
- or Patient deteriorated while on a PAH monotherapy

or

- Bosentan is to be used as PAH triple therapy

and

- Patient is on the lung transplant list
- or Patient is presenting acutely with idiopathic pulmonary arterial hypertension (IPAH) in New York Heart Association/World Health Organization (NYHA/WHO) Functional Class IV
- or Patient is deteriorating rapidly to NYHA/WHO Functional Class IV who may be lung transplant recipients in the future, if their disease is stabilised
- or Patient has PAH associated with the scleroderma spectrum of diseases (APAHSSD) who have no major morbidities and are deteriorating despite combination therapy

or

- In-hospital stabilisation in emergency situations

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Bosentan - continued

CONTINUATION – Pulmonary arterial hypertension

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

- Bosentan is to be used as PAH monotherapy
and
 Patient is stable or has improved while on bosentan

or

- Bosentan is to be used as PAH dual therapy
and
 Patient has tried a PAH monotherapy for at least three months and either failed to respond or later deteriorated

or

- Bosentan is to be used as PAH triple therapy
and
- Patient is on the lung transplant list
 - or
 - Patient is presenting acutely with idiopathic pulmonary arterial hypertension (IPAH) in New York Heart Association/World Health Organization (NYHA/WHO) Functional Class IV
 - or
 - Patient is deteriorating rapidly to NYHA/WHO Functional Class IV who may be lung transplant recipients in the future, if their disease is stabilised
 - or
 - Patient has PAH associated with the scleroderma spectrum of diseases (APAHSSD) who have no major morbidities and are deteriorating despite combination therapy

I confirm that the above details are correct:

Signed: Date: